Cargando…

Oncolytic Adenovirus with SPAG9 shRNA Driven by DD3 Promoter Improved the Efficacy of Docetaxil for Prostate Cancer

Prostate cancer (PCa) is a common malignant tumor of the male urinary system and ranks the second in the causes of tumor-related deaths. Differential display code 3 (DD3) is a noncoding gene that is specifically expressed in PCa. High expression of sperm-associated antigen 9 (SPAG9) is closely relat...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Meng, Wei, Fu-kun, Wu, Chuang, Xu, Zi-yang, Mao, Li-jun, Yang, Dong-rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9078851/
https://www.ncbi.nlm.nih.gov/pubmed/35535313
http://dx.doi.org/10.1155/2022/7918067
_version_ 1784702428983066624
author Lu, Meng
Wei, Fu-kun
Wu, Chuang
Xu, Zi-yang
Mao, Li-jun
Yang, Dong-rong
author_facet Lu, Meng
Wei, Fu-kun
Wu, Chuang
Xu, Zi-yang
Mao, Li-jun
Yang, Dong-rong
author_sort Lu, Meng
collection PubMed
description Prostate cancer (PCa) is a common malignant tumor of the male urinary system and ranks the second in the causes of tumor-related deaths. Differential display code 3 (DD3) is a noncoding gene that is specifically expressed in PCa. High expression of sperm-associated antigen 9 (SPAG9) is closely related to tumorigenesis of PCa, and SPAG9 is a therapeutic target for PCa. In this study, a new oncolytic adenovirus DD3-ZD55-SPAG9 was constructed by using DD3 promoter to enhance the efficacy and safety of adenovirus. The combined use of DD3-ZD55-SPAG9 and docetaxel showed that DD3-ZD55-SPAG9 significantly improved the anti-tumor efficacy of docetaxel in PCa both in vitro and in vivo. The mechanism was related to the induction of tumor cell apoptosis and the inhibition of tumor cell invasion. In conclusion, DD3-ZD55-SPAG9 combined with docetaxel is an effective strategy for PCa therapy.
format Online
Article
Text
id pubmed-9078851
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-90788512022-05-08 Oncolytic Adenovirus with SPAG9 shRNA Driven by DD3 Promoter Improved the Efficacy of Docetaxil for Prostate Cancer Lu, Meng Wei, Fu-kun Wu, Chuang Xu, Zi-yang Mao, Li-jun Yang, Dong-rong J Oncol Research Article Prostate cancer (PCa) is a common malignant tumor of the male urinary system and ranks the second in the causes of tumor-related deaths. Differential display code 3 (DD3) is a noncoding gene that is specifically expressed in PCa. High expression of sperm-associated antigen 9 (SPAG9) is closely related to tumorigenesis of PCa, and SPAG9 is a therapeutic target for PCa. In this study, a new oncolytic adenovirus DD3-ZD55-SPAG9 was constructed by using DD3 promoter to enhance the efficacy and safety of adenovirus. The combined use of DD3-ZD55-SPAG9 and docetaxel showed that DD3-ZD55-SPAG9 significantly improved the anti-tumor efficacy of docetaxel in PCa both in vitro and in vivo. The mechanism was related to the induction of tumor cell apoptosis and the inhibition of tumor cell invasion. In conclusion, DD3-ZD55-SPAG9 combined with docetaxel is an effective strategy for PCa therapy. Hindawi 2022-04-30 /pmc/articles/PMC9078851/ /pubmed/35535313 http://dx.doi.org/10.1155/2022/7918067 Text en Copyright © 2022 Meng Lu et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Lu, Meng
Wei, Fu-kun
Wu, Chuang
Xu, Zi-yang
Mao, Li-jun
Yang, Dong-rong
Oncolytic Adenovirus with SPAG9 shRNA Driven by DD3 Promoter Improved the Efficacy of Docetaxil for Prostate Cancer
title Oncolytic Adenovirus with SPAG9 shRNA Driven by DD3 Promoter Improved the Efficacy of Docetaxil for Prostate Cancer
title_full Oncolytic Adenovirus with SPAG9 shRNA Driven by DD3 Promoter Improved the Efficacy of Docetaxil for Prostate Cancer
title_fullStr Oncolytic Adenovirus with SPAG9 shRNA Driven by DD3 Promoter Improved the Efficacy of Docetaxil for Prostate Cancer
title_full_unstemmed Oncolytic Adenovirus with SPAG9 shRNA Driven by DD3 Promoter Improved the Efficacy of Docetaxil for Prostate Cancer
title_short Oncolytic Adenovirus with SPAG9 shRNA Driven by DD3 Promoter Improved the Efficacy of Docetaxil for Prostate Cancer
title_sort oncolytic adenovirus with spag9 shrna driven by dd3 promoter improved the efficacy of docetaxil for prostate cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9078851/
https://www.ncbi.nlm.nih.gov/pubmed/35535313
http://dx.doi.org/10.1155/2022/7918067
work_keys_str_mv AT lumeng oncolyticadenoviruswithspag9shrnadrivenbydd3promoterimprovedtheefficacyofdocetaxilforprostatecancer
AT weifukun oncolyticadenoviruswithspag9shrnadrivenbydd3promoterimprovedtheefficacyofdocetaxilforprostatecancer
AT wuchuang oncolyticadenoviruswithspag9shrnadrivenbydd3promoterimprovedtheefficacyofdocetaxilforprostatecancer
AT xuziyang oncolyticadenoviruswithspag9shrnadrivenbydd3promoterimprovedtheefficacyofdocetaxilforprostatecancer
AT maolijun oncolyticadenoviruswithspag9shrnadrivenbydd3promoterimprovedtheefficacyofdocetaxilforprostatecancer
AT yangdongrong oncolyticadenoviruswithspag9shrnadrivenbydd3promoterimprovedtheefficacyofdocetaxilforprostatecancer